

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number
WO 2004/004739 A1

(51) International Patent Classification⁷: **A61K 31/58**,
47/38, 9/107

(21) International Application Number:
PCT/JP2003/008410

(22) International Filing Date: 2 July 2003 (02.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2002-193399 2 July 2002 (02.07.2002) JP

(71) Applicant (for all designated States except US): **TEIJIN LIMITED** [JP/JP]; 6-7, Minamihommachi 1-chome, Chuo-ku, Osaka-shi, Osaka 541-0054 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **NISHIBE, Yoshihisa** [JP/JP]; c/o Teijin Limited, Iwakuni Research Center, 2-1, Hinode-cho, Iwakuni-shi, Yamaguchi 740-0014 (JP).

NAGANO, Atsuhiko [JP/JP]; c/o Teijin Limited, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065 (JP). **TAKANASHI, Kazuya** [JP/JP]; c/o Teijin Limited, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065 (JP). **UEJIMA, Yasuhide** [JP/JP]; c/o Teijin Limited, Tokyo Research Center, 3-2, Asahigaoka 4-chome, Hino-shi, Tokyo 191-0065 (JP).


(74) Agent: **MIHARA, Hideko**; c/o Teijin Intellectual Property Center Limited, 1-1, Uchisaiwaicho 2-chome, Chiyoda-ku, Tokyo 100-0011 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: **CICLESONIDE-CONTAINING STERILE AQUEOUS SUSPENSION**



(57) Abstract: The present invention provides a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the concentration of ciclesonide after autoclaving is 95 % or more comparing to that before autoclaving. Also the present invention provides a method of manufacturing a ciclesonide-containing sterile aqueous suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.



Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

DESCRIPTION

CICLESONIDE-CONTAINING STERILE AQUEOUS SUSPENSION5 Field of Invention

The present invention relates to a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving.

Besides, the present invention relates to a method of manufacturing a ciclesonide-containing sterile aqueous
10 suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.

Background Art

The pharmaceutical composition of the present invention is a
15 suspension. The suspension can be obtained by suspending a water-insoluble drug(active ingredient) in aqueous medium uniformly. The suspension can be administered in a specific dosage form. Not only a stability of pharmaceutical compositions during storage, but also a high retentivity of
20 drug in the administration site such as nasal cavity can be obtainable by using suspending agents with thixotropic property.

Therefore, the aqueous suspension has been recognized as a useful dosage form and many suspension products have been
25 available on the market.

It is potentially easy for microorganism such as bacteria to proliferate in the aqueous suspension due to its high moisture environment.

Therefore, preservatives are necessary to be added in such
30 aqueous suspension for supplying the market. Generally, as such preservatives, benzalkonium chloride, benzethonium chloride, phenylethyl alcohol or paraoxybenzoic acid esters are used. However, these preservatives are undesirable for use because the damages on mucous membrane etc. as reported
35 in not a few literatures.

For avoiding proliferation of microorganism without preservatives in aqueous formulation, several methods mentioned-below are actually used in general.

The first method is to prepare an aqueous formulation from sterilized ingredients under aseptic condition. The second method is to prepare an aqueous formulation from non-sterilized ingredients, and then, the obtained aqueous formulation is sterilized before or after filling in bottles. In the case of suspension, with respect to the first method, Karlsson et al. disclosed a steroid-containing composition sterilized by dry heat sterilization (WO99/25359). To provide the sterile aqueous suspension, however, it is needed that the suspension has to be prepared under aseptic condition throughout the manufacturing process with sterilized ingredients including steroid, indicating that large and special manufacturing plant is necessary.

On the other hand, as the second method that is simpler than the first one from the viewpoint of equipments, some specific methods have been suggested as follows.

Firstly, filtration. However this method of sterilization is not applicable to suspension in general, because the suspension contains insoluble particles.

Secondly, radiation sterilization. For example, Illum et al. recommended a sterilization process for steroid-containing aqueous suspension by beta ray or gamma ray irradiation (Arch. Pharm. Chemi. Sci., Ed.2, 1974, pp.167-174). However, it is known that many compounds including steroids and other possible ingredients are degraded by beta ray or gamma ray irradiation and then it is difficult to guarantee the security of the degradation products. Therefore, the sterilization methods recommended by Illum et al. are not unlikely applicable to pharmaceutical compositions in actuality.

Thirdly, autoclaving. The autoclaving is one of very common sterilization processes for sterilizing of pharmaceutical compositions. Since the autoclaving is done by heating at 121

degrees C, the method cannot be adopted for unstable drugs in the presence of water at such high temperature. But the third method, the autoclaving, is the most useful sterilizing method as long as the drug is stable enough not to be degraded under such high temperature.

However, there are still two problems to be solved as indicated below.

First, ciclesonide did not seem to be stable chemically at such high temperature, because ciclesonide has an acetal structure in its 16 and 17 positions.

Secondly, it is known that a drug content uniformity (The term "drug content uniformity" means that the drug concentrations sampled from any portions (ex. upper portion, middle portion or lower portion) of the suspension are almost same.) of aqueous suspension containing a water-insoluble drug tends to be depressed by autoclaving, even if the drug is chemically stable. Such a phenomenon, the depression of the content uniformity, is explained that some particles of water-insoluble drug that are once dissolved or partly dissolved to smaller particles under such high temperature appeared again as various size of particles during subsequent cooling, leading to wider range of particle size distribution in suspension.

O'Neill et al. suggested a method by adding saturated concentration of sodium chloride for avoiding depression of the content uniformity of water insoluble drug (US 3,962,430). But, in case adding the saturated concentration of sodium chloride solution, osmotic pressure of the aqueous suspension becomes extremely high. Or the suspension becomes unstable, because the important factor to maintain the physical stability of suspension is matrix network resulted mainly from hydrogen bond that is easily destroyed by high ionic strength. The patent application by Nagano et al. (WO 01/28562) described the aqueous pharmaceutical composition having less than 290 mOsm osmotic pressure comprising ciclesonide and hydroxypropylmethylcellulose ("HPMC" hereinafter). In

addition, the patent application by Nagano et al. (WO 01/28563) described the aqueous pharmaceutical composition comprising ciclesonide and HPMC.

However, Nagano et al. did not mention or suggest sterilizing the composition by autoclaving. Furthermore, Nagano et al. disclosed in these specifications that preservatives might be added to the pharmaceutical composition.

Therefore, there is no motivation concerning the composition without preservatives in both specifications.

The object of the present invention is to provide a ciclesonide-containing sterile aqueous suspension without preservatives.

Further, the other object of the present invention is to provide such a ciclesonide-containing sterile aqueous suspension that can maintain content uniformity of ciclesonide.

The above objects of the present invention have been achieved by discovering that ciclesonide content in the ciclesonide containing aqueous suspension is not depressed by autoclaving, namely, ciclesonide is not degraded by autoclaving in the aqueous suspension.

Further, the above objects of the present invention have been achieved by discovering that the uniformity of ciclesonide content can be maintained when hydroxypropylmethylcellulose is coexisted, even after sterilization by autoclaving.

Brief Description of the Drawing

Figure 1 shows ciclesonide concentration before autoclave, and corresponds to Table 2. Legends in Figure 1 mean as follows.

● of 1: Ex.1 lower, ▲ of 2: Ex.1 middle, × of 3: Ex.1 upper

● of 4: C.Ex.3 lower, ▲ of 5: C.Ex.3 middle, × of 6: C.Ex.3 upper

● of 7: C.Ex.4 lower, ▲ of 8: C.Ex.4 middle, × of 9: C.Ex.4 upper

● of 10: C.Ex.5 lower, ▲ of 11: C.Ex.5 middle, × of 12: C.Ex.5 upper

● of 13: C.Ex.6 lower, ▲ of 14: C.Ex.6 middle, × of 15: C.Ex.6 upper

● of 16: C.Ex.7 lower, ▲ of 17: C.Ex.7 middle, × of 18: C.Ex.7 upper

Figure 2 shows ciclesonide concentration after autoclave, and

corresponds to Table 3. Legends in Figure 2 mean same as those in Figure 1.

Disclosure of the Invention

5 The present invention provides a ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the concentration of ciclesonide after autoclaving is 95 % or more comparing to that before autoclaving.

Also the present invention provides the
10 ciclesonide-containing sterile aqueous suspension sterilized by autoclaving, wherein the suspension contains hydroxypropylmethylcellulose.

Further the present invention provides a method of manufacturing a ciclesonide-containing sterile aqueous
15 suspension comprising the step of sterilization by autoclaving a ciclesonide-containing aqueous suspension.

Embodiment for Carrying Out the Invention

Ciclesonide used in the present invention is a kind of steroids,
20 and represented by the chemical name of (11 β , 16 α)-16,17-[cyclohexylmethylenebis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4,-diene-3,20-dione.

The concentration of ciclesonide after autoclaving is 95 % or more comparing to that before autoclaving in the present
25 invention. Further, according to the condition of the autoclaving, the concentration of ciclesonide after autoclaving may be 98 % or more comparing to that before autoclaving.

Chemically unstable substances are usually degraded by
30 autoclaving or even heating. For example, budesonide (chemical name:

16 α ,17-[(1RS)-butylidene-bis(oxy)]-11 β ,21-dihydroxypregna-1,4-diene-3,20-dione), a kind of steroids, same class of drugs as ciclesonide, is degraded by autoclaving procedure.

35 But surprisingly, ciclesonide of the present invention is not

degraded by autoclaving procedure though ciclesonide has an acetal structure in its 16,17 position.

The concentration of ciclesonide in the present invention is not specified. Preferably, the concentration of the
5 ciclesonide is from 0.01 %w/w to 10%w/w, more preferably, from 0.01 %w/w to 3 %w/w, relative to the total amount of the suspension.

HPMC is a kind of wetting agents. HPMC is heteropolymer composed of a mixture of methyl and hydroxypropyl ether of
10 cellulose derivative. HPMC is used for an additive of pharmaceutical composition in general. HPMC has several grades classified depending on content of methoxyl group and hydroxypropoxyl group. Although any grade can be used for the suspension of the present invention, specific examples are
15 hydroxypropylmethylcellulose 2208,
hydroxypropylmethylcellulose 2906, or
hydroxypropylmethylcellulose 2910. These grades of HPMC are available as Metolose 90SH, Metolose 65SH or Metolose 60SH (by
Shin-Etsu Chemical CO.), respectively. Preferably,
20 hydroxypropylmethylcellulose 2910, i.e. Metolose 60SH, is suitable.

Although said HPMC may be present at any concentration, its concentration is preferably from 0.01%w/w to 5%w/w, more preferably from 0.05%w/w to 1%w/w, relative to the total amount
25 of the suspension.

HPMC is effective for overcoming the depression of ciclesonide content uniformity by autoclaving in the present invention with no need to add salt such as sodium chloride. As mentioned below, HPMC is superior in overcoming the depression of
30 ciclesonide content uniformity to general surfactants used as wetting agents.

Although hydroxypropylcellulose (HPC) or carmellose sodium (CMCNa) can be illustrated as cellulose ethers, they are not suitable due to the followings. HPC forms gel during the
35 autoclaving process, resulting in poor uniformity of drug

content besides undesirable look by appearance.

Suspending agents can be added to the present suspension, if desired. Any suspending agents can be applied in the present invention. Examples of suspending agents include polyvinyl alcohol, povidone, cellulose, carbomer, poloxamer, carmellose sodium and xanthangum. Complexes of water insoluble substances and dispersants may be used as the suspending agent.

Example of the water-insoluble substance includes microcrystalline cellulose, examples of the dispersants include carmellose sodium and xanthangum. Preferably, complex of microcrystalline cellulose and carmellose sodium is suitable for the present invention. The complex called microcrystalline cellulose -carmellose sodium in general, is available as AvicelTM RC-591NF from Asahi Kasei Co., Ltd.

The concentration of suspending agent of the present invention is preferably from 0.1 %w/w to 10 %w/w, more preferably 0.5 %w/w to 5 %w/w, relative to the total amount of the suspension. Any method for dispersing ciclesonide in an aqueous medium optionally including HPMC and suspending agent may be used for the production of the ciclesonide-containing aqueous suspension in the present invention, a specific example of which is a method that uses commercially available equipment such as a mixer and an emulsifier. Preferably, a vacuum emulsifier is suitable for evacuating bubbles growing in the dispersing process. It is preferable for the condition to be set that leads to both good drug content uniformity and maximum thixotropic property.

The autoclaving of the present invention is a method of sterilizing in autoclaving equipment by steam with high pressure and temperature. A proper condition should be set depending on the equipment used or the scale of bulk suspension to be dealt with. Generally, the autoclaving is carried out at 115 degrees C for 30 minutes, at 121 degrees C for 20 minutes or at 126 degrees C for 15 minutes.

The suspension can be autoclaved consecutively in the same

container used for the dispersion, or after filling in another container. In the case of former method, with the equipment having special apparatus, both dispersion and sterilization can be done.

- 5 After sterilization process by autoclaving, the ciclesonide-containing sterile aqueous suspension of the present invention should be packaged in a container-closure system that has a structure avoiding contamination of microorganism such as bacteria. Several examples of such
- 10 system are proposed. A filtering system equipped with the device for the avoidance of microorganism contamination accompanied with air flow after the actuation (spraying or dropping) is one example of such system. Another is an anti-microbial system such that the material to contact with
- 15 the formulation is coated with silver. Or the combination of the above-mentioned systems is suitable. Preservative-free-system obtained from Pfeiffer is an example of the aforementioned system, but not limited to Pfeiffer's system.
- 20 The ciclesonide-containing sterile aqueous suspension of the present invention can be administered via any other routes than nasal route such as ophthalmic, transdermal or oral route. According to the present invention as described above, a ciclesonide-containing sterile aqueous suspension without
- 25 preservatives is provided. In addition, according to the present invention as described above, a ciclesonide-containing sterile aqueous suspension is provided that has an excellent content uniformity of ciclesonide. Thus, the present invention has extremely high significance
- 30 in terms of overcoming the possible side effects caused by preservatives.

Examples

- The following provides an explanation of the present invention
- 35 through its Examples.

Ciclesonide used in the present invention was obtained from Altana Pharma AG, the microcrystalline cellulose-carmellose sodium from Asahi Kasei Co., Ltd. (AvicelTM RC-A591NF), hydroxypropylmethylcellulose 2910 from Shin-Etsu Chemical Co., Ltd., (TC-5RWTM), budesonide and beclomethasone dipropionate from Sigma-Aldrich Co. Desk Autoclave IST-150 from Chiyoda Manufacturing Co., Ltd. was used for autoclaving.

Example 1, Comparative Examples 1-2

10 Preparation of ciclesonide-containing aqueous pharmaceutical suspension

White uniform aqueous pharmaceutical suspension containing the ingredients indicated below was prepared.

15 Composition;

Ciclesonide	0.1 % w/w
Microcrystalline Cellulose-Carmellose Sodium	1.7 % w/w
Hydroxypropylmethylcellulose 2910	0.1 % w/w
Purified Water	300 mL

20

An aqueous suspension containing budesonide instead of ciclesonide of Example 1 was prepared as Comparative Example 1. An aqueous suspension containing beclomethasone dipropionate instead of ciclesonide of Example 1 was prepared as Comparative Example 2. Suspensions of Comparative Examples 1 and 2 were white and uniform.

Investigation 1

30 Comparison of chemical stability of drug in the aqueous suspension against autoclaving

Procedure

The suspension of Example 1 was put into a 500 mL glass container with a screw cap and sterilized by autoclaving at 121 degrees C for 20 minutes. Subsequently, after mixing the suspension in the glass container, the ciclesonide concentration was

quantified by HPLC.

The recovery rate of ciclesonide after the autoclaving was calculated by taking the ciclesonide concentration before the autoclaving to be 100%. The recovery rates of budesonide and
5 beclomethasone dipropionate after the autoclaving were calculated by the same method.

Those rates are shown in Table 1.

Table 1

10

Preparation	Recovery rate (%)
Example 1	100.1
Comparative Example 1	26.3
Comparative Example 2	78.1

Investigation 2

Comparison of ciclesonide concentration uniformity of aqueous suspensions with various wetting agents before and after
15 autoclaving

Procedure

Ciclesonide aqueous suspension containing wetting agents indicated below instead of hydroxypropylcellulose 2910 were prepared as Comparative Examples 3-7. Tween 80 used in the
20 present invention was obtained from Nikko Chemicals Co., (Nikkol TO-10M), Tween 60 from Nikko Chemicals Co., Ltd. (Nikkol TS-10), Polyoxyethylene hydrogenated castor oil 60 from Nikko Chemicals Co., Ltd. (Nikkol HCO-60), hydroxypropylcellulose from Shin-Etsu Chemical Co.,
25 Ltd. (hydroxypropylcellulose) and carmellose sodium from Daiichi Kogyo Pharmaceutical Co., Ltd. (serogen).

Comparative example 3 : Tween 80 0.025 % w/w

Comparative example 4 : Tween 60 0.025 % w/w

30 Comparative example 5 : Polyoxyethylene Hydrogenated Castor Oil 60 0.2 % w/w

Comparative example 6 : Hydroxypropylcellulose (HPC) 0.1 % w/w
Comparative example 7 : Carmellose Sodium 0.15 % w/w

Each concentration of the wetting agent of Comparative
5 Examples 3-7 was an optimum value as a wetting agent for
suspension respectively. Therefore, by comparing with
Example 2 and Comparative Examples 3-7, we can recognize
differences between HPMC and other wetting agents (Tween 80,
Tween 60, Polyoxyethylene Hydrogenated Castor Oil 60, HPC and
10 Carmellose Sodium).

On 3-hour-leaving after the preparation of the above-mentioned
suspension, dispersion states of solid particles in the
suspension were observed. Furthermore about 2 g of the
suspension was sampled from upper, middle and lower portions
15 of the bulk suspension in the glass container, respectively,
followed by the determination of ciclesonide concentration in
each portion.

Appearances of the ciclesonide aqueous suspension and the
uniformity of the ciclesonide concentration before
20 autoclaving are shown in Table 2 and Figure 1.

Table 2

Preparation	Appearance	Ciclesonide concentration* (%) (versus theoretical value)		
		Upper portion of the bulk suspension (n=5)	Middle portion of the bulk suspension (n=5)	Lower portion of the bulk suspension (n=5)
Example 2	white and uniform suspension	99.8, 100.9, 99.9 100.1, 100.1	99.9, 101.1, 99.8 99.8, 100.0	99.0, 100.2, 100.6 100.1, 101.0
Comparative Example 3	Ditto	99.1, 99.9, 100.5 100.9, 99.8	100.3, 99.8, 101.2, 99.8, 99.2	100.1, 100.0, 100.6, 99.7, 100.2
Comparative Example 4	Ditto	99.8, 100.3, 99.6 98.9, 100.2	99.7, 100.5, 99.9 99.8, 101.0	99.3, 100.2, 99.0 101.3, 99.8
Comparative Example 5	Ditto	100.8, 101.2, 99.2 99.0, 100.6	100.2 99.6, 99.4 100.2 99.7	99.5, 99.4, 100.3 100.2, 101.7
Comparative Example 6	Ditto	101.6, 99.0, 99.8 100.3, 100.2	99.8, 101.2, 100.0 99.8, 100.4	99.8, 102.0, 100.2 99.8, 100.3
Comparative Example 7	Ditto	99.7, 99.9, 99.7 101.6, 100.2	100.2, 101.1, 100.8, 100.0, 99.3	99.4, 100.2, 99.9 100.3, 99.7

* : Ratio (percentage) of the ciclesonide concentration calculated from the peak area on high performance liquid chromatography of applied sample to the theoretical ciclesonide concentration**.

** : Theoretical ciclesonide concentration means the weight of ciclesonide per the weight of total suspension in

manufacturing.

Then as the next step, the suspensions of Example 2 and Comparative Examples 3-7 in 500 mL glass container were
5 sterilized by autoclaving at 121 degrees C for 20 minutes. Subsequently, the glass container was took out from the equipment for autoclave. After 3-hour-leaveing, the dispersion state of the solid particles in each suspension was
10 observed. Furthermore about 2g of the suspension were sampled from upper, middle and lower portions of the bulk suspension in the glass container, respectively, followed by the determination of ciclesonide concentration of each portion .
Appearances of the ciclesonide aqueous suspension and the uniformity of the ciclesonide concentration after autoclaving
15 are shown in Table 3 and Figure 2.

Table 3

Preparation	Appearance	Ciclesonide concentration* (%) (versus theoretical value)		
		Upper portion of the bulk suspension (n=5)	Middle portion of the bulk suspension (n=5)	Lower portion of the bulk suspension (n=5)
Example 2	no change	100.0, 101.0, 99.9 99.8, 100.1	101.2, 98.9, 99.9 100.5, 100.3	99.0, 99.8, 101.2 100.4, 100.0
Comparative Example 3	ditto	92.2, 94.9, 89.5 95.9, 93.7	94.8, 103.5, 98.8 100.0, 92.9	109.9, 113.0, 98.6 106.6, 100.2
Comparative Example 4	ditto	90.2, 94.9, 92.2 85.9, 100.5	99.4, 106.5, 94.9 105.4, 93.0	100.9, 112.5, 98.8 109.3, 104.4
Comparative Example 5	ditto	93.8, 96.1, 88.8 95.9, 90.6	100.9 92.6, 98.1 104.1 99.9	110.5, 99.0, 98.6 115.5, 100.7
Comparative Example 6	large solid appeared	101.6, 100.0, 99.6 99.8, 100.0	100.2, 99.9, 99.7 100.5, 100.3	99.5, 99.0, 101.0 99.4, 100.9
Comparative Example 7	no change	92.5, 96.6, 100.0 95.6, 83.2	94.3, 105.1, 93.8 101.8, 92.2	111.1, 123.1, 99.9 107.3, 100.3

* : Same as Table 2.

CLAIMS

1. A ciclesonide-containing sterile aqueous suspension
sterilized by autoclaving, wherein the concentration of
5 ciclesonide after autoclaving is 95 % or more comparing
to that before autoclaving.
2. The ciclesonide-containing sterile aqueous suspension
according to claim 1 additionally containing
hydroxypropylmethylcellulose.
- 10 3. The ciclesonide-containing sterile aqueous suspension
according to claim 2, wherein the
hydroxypropylmethylcellulose is
hydroxypropylmethylcellulose 2910.
4. A method of manufacturing a ciclesonide-containing
15 sterile aqueous suspension comprising the step of
sterilization by autoclaving a ciclesonide-containing
aqueous suspension.
5. The method of manufacturing a ciclesonide-containing
sterile aqueous suspension according to claim 4, wherein
20 the concentration of ciclesonide after autoclaving is
95 % or more comparing to that before autoclaving.
6. The method of manufacturing a ciclesonide-containing
sterile aqueous suspension according to any one of claims
4 through 5, wherein the ciclesonide-containing aqueous
25 suspension additionally contains
hydroxypropylmethylcellulose.
7. The method of manufacturing a ciclesonide-containing
sterile aqueous suspension according to claim 6, wherein
the hydroxypropylmethylcellulose is
30 hydroxypropylmethylcellulose 2910.

Figure 1





Figure 2



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/08410

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ A61K 31/58, 47/38, 9/107

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ A61K 31/58, 47/38, 9/107

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA (STN), REGISTRY (STN)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 01/028563 A (ALTANA PHARMA AG) 2001.04.26, Whole document, &AU 200079532 A &BR 200014880 A &EP 1227817 A1 &KR 2002060205 A &CN 1379673 A &JP 2003-512330 A	1-7
Y	WO 01/028562 A (ALTANA PHARMA AG) 2001.04.26, Whole document, &AU 200079531 A &BR 200014878 A &EP 1225902 A1 &KR 2002059627 A &CN 1379674 A &JP 2003-512329 A	1-7
Y	EP 233849 A (KABIVUTRYN AB) 1987.08.26, Whole document, &JP 62-192322 A &US 5028600 A	1-7



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

06.10.03

Date of mailing of the international search report

21.10.03

Name and mailing address of the ISA/IP

Japan Patent Office

3-4-3, Kasumigaseki, Chiyoda-ku, Tokyo 100-8915, Japan

Authorized officer

YUMIKO YAHARA

Telephone No. +81-3-3581-1101 Ext. 3451



4C

9261

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/08410

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99/25359 A (ASTRAZENECA AB) 1999.05.27, Whole document &AU 9912666 A &EP 1032396 A1 &CN 1285750 A &KR 200103288 A &JP 2001-523638 A &US 2002/0065256 A1 &US 6392036 B1	1-7
A	WO 99/32156 A (BAYER AG) 1999.07.01, Whole document &AU 9916301 A &US 6066292 A &EP 1039937 A2 &CN 1282256 A &KR 2001033306 A &JP 2001-526089 A	1-7
A	JP 2001-048807 A (WAKAMOTO PHARM CO LTD) 2001.02.20, Whole document (Family:None)	1-7